Search
Eli Lilly Invests $2.75 Billion in Collaboration with Insilico Medicine to Promote AI-Driven Drug Discovery
5 hour ago /
Read about 0 minute
Author：小编
On March 29, 2026, U.S. pharmaceutical company Eli Lilly entered into a $2.75 billion collaboration with Hong Kong-listed Insilico Medicine to globalize new drugs developed by Insilico using AI. Insilico Medicine will receive an upfront payment of $115 million, with the remaining amount to be paid based on regulatory approvals and commercialization milestones, along with royalties from drug sales. The two companies have been collaborating since 2023, and this partnership will accelerate the screening of drug candidates across multiple disease areas.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
